2,611 Shares in ICU Medical, Inc. (NASDAQ:ICUI) Purchased by Truist Financial Corp

Truist Financial Corp purchased a new stake in ICU Medical, Inc. (NASDAQ:ICUI) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 2,611 shares of the medical instruments supplier’s stock, valued at approximately $310,000.

Other hedge funds have also bought and sold shares of the company. Motco purchased a new position in shares of ICU Medical during the 1st quarter valued at approximately $29,000. Innealta Capital LLC purchased a new position in ICU Medical in the second quarter valued at $32,000. GAMMA Investing LLC raised its position in shares of ICU Medical by 75.1% in the first quarter. GAMMA Investing LLC now owns 310 shares of the medical instruments supplier’s stock worth $33,000 after acquiring an additional 133 shares during the period. EntryPoint Capital LLC raised its position in shares of ICU Medical by 731.5% in the first quarter. EntryPoint Capital LLC now owns 449 shares of the medical instruments supplier’s stock worth $48,000 after acquiring an additional 395 shares during the period. Finally, Russell Investments Group Ltd. boosted its stake in shares of ICU Medical by 46.4% during the 1st quarter. Russell Investments Group Ltd. now owns 546 shares of the medical instruments supplier’s stock worth $59,000 after acquiring an additional 173 shares in the last quarter. Hedge funds and other institutional investors own 96.10% of the company’s stock.

Insider Buying and Selling

In other ICU Medical news, CEO Vivek Jain sold 12,000 shares of the stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $178.46, for a total value of $2,141,520.00. Following the completion of the sale, the chief executive officer now owns 104,593 shares in the company, valued at approximately $18,665,666.78. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other ICU Medical news, VP Daniel Woolson sold 2,502 shares of the firm’s stock in a transaction on Friday, August 30th. The stock was sold at an average price of $163.22, for a total value of $408,376.44. Following the completion of the sale, the vice president now directly owns 13,107 shares of the company’s stock, valued at $2,139,324.54. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Vivek Jain sold 12,000 shares of the business’s stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $178.46, for a total transaction of $2,141,520.00. Following the transaction, the chief executive officer now directly owns 104,593 shares in the company, valued at approximately $18,665,666.78. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 40,552 shares of company stock worth $6,679,322. 6.70% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the company. Raymond James lifted their price target on ICU Medical from $158.00 to $190.00 and gave the company an “outperform” rating in a research note on Thursday, September 12th. StockNews.com upgraded ICU Medical from a “hold” rating to a “buy” rating in a research report on Thursday, September 12th. Needham & Company LLC reiterated a “hold” rating on shares of ICU Medical in a research report on Thursday, October 10th. Jefferies Financial Group started coverage on shares of ICU Medical in a research note on Monday, October 14th. They issued a “hold” rating and a $183.00 price target on the stock. Finally, KeyCorp upped their price objective on shares of ICU Medical from $147.00 to $198.00 and gave the stock an “overweight” rating in a research report on Tuesday. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $170.25.

ICU Medical Price Performance

Shares of ICU Medical stock opened at $180.94 on Friday. The company has a debt-to-equity ratio of 0.76, a current ratio of 2.41 and a quick ratio of 1.08. ICU Medical, Inc. has a 12 month low of $78.28 and a 12 month high of $188.53. The stock has a market capitalization of $4.41 billion, a P/E ratio of -73.85 and a beta of 0.66. The business has a 50 day simple moving average of $170.09 and a two-hundred day simple moving average of $132.06.

ICU Medical (NASDAQ:ICUI) last announced its quarterly earnings data on Wednesday, August 7th. The medical instruments supplier reported $1.56 earnings per share for the quarter, beating analysts’ consensus estimates of $1.00 by $0.56. ICU Medical had a positive return on equity of 5.01% and a negative net margin of 3.07%. The company had revenue of $596.50 million for the quarter, compared to analyst estimates of $556.64 million. During the same quarter last year, the firm posted $1.58 EPS. The firm’s revenue for the quarter was up 8.6% on a year-over-year basis. As a group, analysts predict that ICU Medical, Inc. will post 3.76 EPS for the current fiscal year.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.